Search in the Abstract Database

Search Abstracts 2015

* = Presenting author

P451 Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies

S. Wang*1, H. Yang2, E. Faust2, Y. Bao1

1AbbVie Inc., Global Health Economics and Outcomes Research, North Chicago, IL, United States, 2Analysis Group, Inc., Boston, MA, United States

Background

Medical treatment options for patients with moderate-to-severe ulcerative colitis (UC) include conventional non-biologic therapies and biologic therapies, mainly tumour necrosis factor inhibitors. The economic burden of UC is substantial, owing partly to hospitalisation costs. The current study aimed to quantify the costs of hospitalisations among UC patients treated with adalimumab and with conventional non-biologic therapies in the United Kingdom (UK), Germany, France, Italy, Spain, and Canada.

Methods

An economic model was developed to estimate the annual hospitalisation costs for 1,000 moderate-to-severe UC patients, assuming they were treated with adalimumab or conventional non-biologic therapies. Rates of UC-related and all-cause hospitalisations for adalimumab and conventional non-biologic therapies among moderate-to-severe UC patients were derived from a publication summarising two Phase-III clinical trials of adalimumab (NCT00385736, NCT00408629)[1]. Unit costs per hospitalisation in the UK, Germany, France, Italy, Spain, and Canada were derived from the literature. All costs were inflated to 2013 in each country's respective currency.

Results

Treatment with adalimumab compared with conventional non-biologic therapies was associated with 101 fewer UC-related and 83 fewer all-cause hospitalisations per 1,000 UC-treated patients during a 1-year period. This finding translated to a UC-related annual cost savings of £292,160 in the UK, €190,528 in Germany, €256,453 in France, €615,221 in Italy, €433,536 in Spain, and CAN$1,156,199 in Canada. Adalimumab-associated all-cause annual cost savings were £249,956 in the UK, €163,005 in Germany, €219,407 in France, €526,351 in Italy, €370,910 in Spain, and CAN$989,182 in Canada.

Conclusion

Treatment with adalimumab compared with conventional non-biologic therapy is associated with fewer UC-related and all-cause hospitalisations and with reduced costs among patients with moderate-to-severe UC.

References:

[1] Feagan BG et al, (2014), Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis , Gastroenterol. 146:110-8